Is quetiapine approved for insomnia in Australia?

No. Quetiapine (brand name Seroquel) is TGA-approved as an antipsychotic for conditions including schizophrenia and bipolar disorder. Prescribing it at low doses (25–50 mg) for insomnia is off-label. Off-label prescribing is legal in Australia, but it means the indication is not covered by the original regulatory evidence base. If you are taking quetiapine for sleep, a conversation with your GP about the current evidence and alternatives is reasonable.

What should someone taking low-dose quetiapine for sleep do now?

Do not stop a prescribed medication without speaking to your GP first. If you are concerned about next-day alertness or driving safety, raise this with your prescriber — particularly if you have obstructive sleep apnoea, a driving-intensive job, or care for dependants overnight. There are alternatives for insomnia, including CBT for insomnia (CBT-I), which has the strongest evidence base, and other pharmacological options worth discussing with your GP.

Quetiapine for insomnia: new RCT data on next-day driving impairment

What just happened

Flinders University researchers published findings on 2 June 2026 from a small but carefully designed trial that puts a familiar off-label prescribing habit in uncomfortable focus: low-dose quetiapine — the antipsychotic used off-label for insomnia more widely than most people realise — helped people sleep, but left them measurably impaired behind the wheel the next morning.

The paper, published in the Annals of the American Thoracic Society, ran fifteen adults through two nights in a sleep laboratory in randomised crossover fashion — one night on 50 mg quetiapine, one on placebo. Participants had both insomnia (specifically, difficulty maintaining sleep) and obstructive sleep apnoea (OSA). After each night they completed a driving simulator task and a sustained attention vigilance test to measure next-day alertness objectively. The sleep data was modestly positive: quetiapine improved total sleep time and reduced the apnoea-hypopnoea index (AHI), the standard measure of sleep apnoea severity. The next-day data was not. Participants on quetiapine had slower reaction times, more lapses in attention, and worse steering control. The researchers described attention lapses as tripling compared to placebo.

Professor Eckert from the Flinders Health and Medical Research Institute, who led the study, stated directly: “Our findings suggest quetiapine should not be used as a routine sleep medication in people with known or possible sleep apnoea, particularly when next-day alertness is critical.”

For a 45-year-old woman whose sleep has been fragmenting — whether from perimenopause, anxiety, pain, or unrecognised sleep apnoea — this finding sits in a complicated place. Because quetiapine at 25 to 50 mg has become quietly common in exactly this setting. It is not an officially approved insomnia treatment in Australia. It is an off-label use of an antipsychotic. And the driving consequences are now legible in objective data for the first time in this combined population.

The both-and

Quetiapine does something measurable for sleep. It also does something measurable to next-day performance. Both are real, and the risk calculus is what matters clinically.

The off-label prescribing reality

Off-label prescribing in Australia is legal and common. GPs use low-dose quetiapine for insomnia because the officially approved insomnia medications — benzodiazepines and Z-drugs (temazepam, nitrazepam, zolpidem) — carry documented tolerance, dependence, and residual sedation risks. Quetiapine at sub-antipsychotic doses was adopted by clinicians as an alternative that did not carry the same dependence profile and had some sedating effect through antihistaminergic and anti-alpha-adrenergic mechanisms.

But the evidence base for this specific off-label use has always been thin. The new trial adds something it previously lacked: objective driving impairment data, in a population that reflects a real clinical pattern — people with both insomnia and OSA, a combination that is underrecognised and particularly common in women over 40.

The sleep apnoea dimension is the key clinical concern

OSA in women is substantially underdiagnosed, in part because women with OSA more often present with insomnia, fatigue, mood disturbance, and headache rather than the snoring and witnessed apnoeas more typical in men. A woman presenting to a GP with sleep fragmentation, daytime fatigue, and low mood in her mid-40s may have OSA as a primary or contributing driver — and may leave that consultation with quetiapine rather than a sleep study referral.

The trial found that quetiapine reduced the AHI — which looks like a benefit for OSA, and in isolation it is. The drug blunts arousal responses, which reduces the frequency of apnoeas. But this comes at the cost of sustained next-day impairment in alertness that the person taking the medication may not subjectively recognise. The paradox is that quetiapine makes the night’s physiology look better while making the day’s function measurably worse.

What the small sample size means

Fifteen participants is a small trial. These findings are directionally important, not definitive. But the pharmacological mechanism that would predict this residual impairment is well understood, and the objective outcome measures — driving simulation and sustained attention — are more reliable than self-report. The Flinders team are appropriately cautious in their language. The signal is clear enough to act on clinically, even before a larger trial confirms it at scale.

The study design also reflects a real patient profile: OSA and insomnia co-occur frequently, and prescribing quetiapine to this group without accounting for the driving risk is now harder to do without awareness.

2 cents

If you are taking low-dose quetiapine for sleep: this is not a reason to stop without speaking to your GP first. Abrupt cessation of any psychotropic medication carries its own risks and is not recommended.

What this research provides is a clearer basis for a specific conversation with your prescriber. Questions worth raising: What is the current evidence for using quetiapine for sleep specifically? Are there alternatives that carry a different next-day performance profile — melatonin, or CBT for insomnia (CBT-I), which has the strongest overall evidence for insomnia and does not carry a pharmacological hangover? Is there any possibility that undiagnosed OSA is driving the sleep fragmentation, which might be better addressed through a sleep study and CPAP pathway?

If you drive regularly, work shifts, care for dependants overnight, or operate equipment, the impairment data from this trial is relevant to your situation. That is worth naming explicitly in your next general practice consultation — not as an accusation toward your prescriber, but as new information that belongs in the decision about what to do next.

This is general health information. Do not stop a prescribed medication without speaking to your prescriber first. Individual clinical circumstances vary widely.

Verdict

Verdict: yes — worth knowing about.

The quetiapine-for-insomnia story has been pharmacologically concerning for some time. This trial adds objective driving impairment data to a risk profile that was previously inferred from mechanism. For women in midlife using low-dose quetiapine for sleep fragmentation — a common off-label use in this population — the data is now specific enough to raise with a GP, particularly if driving is part of daily life.